Provectus Biopharmaceuticals
Tim Scott is the CEO of Provectus Biopharmaceuticals.
This person is not in any offices
Provectus Biopharmaceuticals
Provectus Biopharmaceuticals is investigating new therapies for the treatment of skin cancer, liver cancer, and breast cancer. Provectus’ investigational oncology drug, PV-10, is an ablative immunotherapy under investigation in solid tumor cancers.